VSTM Q1 2024 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$28M

Net Income

-$34M

EPS (Diluted)

$-1.26

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$124M

Total Liabilities

$77M

Stockholders' Equity

$46M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$28M	-$19M	-45.1%
Net Income	-$34M	-$16M	-115.5%